ScribnerB.H., BuriR., CanerJ.E., HegstromR., BurnellJ.M.The treatment of chronic uremia by means of intermittent hemodialysis: a preliminary report. Trans Am Soc Artif Intern Organs.1960; 6: 114–122.
2.
ChertowG.M., LevinN.W., BeckG.J.. FHN Trial Group. In-center hemodialysis 6 times per week versus 3 times per week. N Engl J Med.2010; 363(24): 2287–2300.
3.
RoccoM.V., LockridgeR.S.Jr., BeckG.J.. Frequent Hemodialysis Network (FHN) Trial Group. The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. Kidney Int.2011; 80(10): 1080–1091.
4.
DavenportA.How best to improve survival in hemodialysis patients: solute clearance or volume control?Kidney Int.2011; 80(10): 1018–1020.
5.
DavenportA., GuraV., RoncoC., BeizaiM., EzonC., RambodE.A wearable haemodialysis device for patients with end-stage renal failure: a pilot study. Lancet.2007; 370(9604): 2005–2010.
6.
GuraA., GuraVictor, RivaraM.B.. A wearable artificial kidney for patients with end-stage renal disease. JCI Insight.2016; 1(8): e86397.
7.
ChevtchikN.V., FedecostanteM., JansenJ.. Upscaling of a living membrane for bioartificial kidney device. Eur J Pharmacol.2016; 790: 28–35.
8.
VillanuevaS., EwertzE., CarrionF.. Mesenchymal stem cell injection ameliorates chronic renal failure in a rat model. Clin Sci (Lond).2011; 121(11): 489–499.
9.
KitamuraM.Renal transfer of genetically engineered cells. J Am Soc Nephrol.2000; 11(Suppl 16): S154–S158.
10.
LanH.Y., MuW., TomitaN.. Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J Am Soc Nephrol.2003; 14(6): 1535–1548.
